DIAGNOS Inc. (CVE:ADK – Get Free Report) shares traded up 21.3% during trading on Friday. The company traded as high as C$0.28 and last traded at C$0.28. Approximately 250,962 shares were traded during trading, an increase of 12% from the average session volume of 224,351 shares. The stock had previously closed at C$0.23.
DIAGNOS Price Performance
The stock has a 50 day moving average of C$0.41 and a two-hundred day moving average of C$0.31. The firm has a market capitalization of C$32.68 million, a P/E ratio of -6.75 and a beta of 0.05. The company has a debt-to-equity ratio of 204.05, a quick ratio of 0.68 and a current ratio of 1.49.
Insider Activity
In other news, Director Robert Dunn bought 105,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was acquired at an average cost of C$0.48 per share, with a total value of C$50,400.00. Following the completion of the purchase, the director owned 2,679,920 shares of the company’s stock, valued at C$1,286,361.60. This represents a 4.08% increase in their ownership of the stock. Insiders own 16.81% of the company’s stock.
About DIAGNOS
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.
Further Reading
- Five stocks we like better than DIAGNOS
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for DIAGNOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIAGNOS and related companies with MarketBeat.com's FREE daily email newsletter.
